We are international
Donate
• videos TEXT SIZE   



XIIth International Myeloma Workshop, Day 2, February 27, 2009

  • 07:00-08:00 Current Approaches to Supportive Care in Myeloma – Breakfast Symposium (Sponsored by Celgene)
  • 08:15-10:15 Multiple Myeloma Microenvironment
  • 10:30-12:30 Phase III Studies
  • 13:30-15:00 Phase I/II Studies
  • 13:30-15:00 Clinical - New Agents
  • 13:30-15:00 Clinical - Basic Biology - Research
  • 15:30-17:30 Complete Response As A Marker Of Patient Outcomes (Sponsored by Millennium/Ortho-Biotech)
Complete Program Listing

2009 IMW Friday Sessions

Multiple Myeloma - Microenvironment
p62 - a Potential Target for Blocking Microenvironmental Support of Myeloma
XIIth International Myeloma Workshop in Washington, DC
David Roodman, M.D.
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Migration and Homing in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Irene Ghobrial, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Genes and Proteins of Myeloma Endothelial Cells to Search Specific Targets of the Tumor Vasculature
XIIth International Myeloma Workshop in Washington, DC
Angelo Vacca, M.D.
University of Bari Medical School
Bari, Italy

The Effect of Novel Antimyeloma Agents on Bone Metabolism
XIIth International Myeloma Workshop in Washington, DC
Evangelos Terpos, M.D.
General Air Force Hospital
Athens, Greece

Phase III Studies IFM, U.S. Europe, Others
(IFM) Phase III Studies that have been Completed by the IFM Group in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Philippe Moreau, M.D.
Hôpital de Nantes
Nantes, France

(IFM) Phase III Studies That are On-going and Future Planned studies by the IFM Group in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Michael Attal,M.D.
Hôpital Purpan
Toulouse, France

(US/Canada) "Phase III Studies That have been Completed, Ongoing and Planned by the US Groups in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Sagar Lonial, M.D.
Emory Clinic
Atlanta, Georgia

(US/Canada) "Phase III Studies That have been Completed, Ongoing and Planned by the Canadian Group in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Donna Reece, M.D.
Princess Margaret Hospital
Toronto, Ontario, Canada

(Europe) "Phase III Studies That have been Completed, Ongoing and Planned by Italian and Spanish Groups in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Mario Boccadoro, M.D.
Ospedale San Giovanni Battista
Torino, Italy

(Europe) "Phase III Studies That have been Completed, Ongoing and Planned by Various Northern European Groups in Multiple Myeloma
XIIth International Myeloma Workshop in Washington, DC
Pieter Sonneveld, M.D.
University Hospital
Rotterdam, Netherlands

Oral Presentations – Clinical – Phase II/III Studies - I
Lenalidomide, bortezomib, and dexamethasone has notable activity in high-risk frontline myeloma
XIIth International Myeloma Workshop in Washington, DC
Paul Richardson, M.D.
Dana-Farber Cancer Institute
Boston, Massachusetts

Bortezomib, dexamethasone, cyclophosphamide, lenalidomide (VDCR) has high efficacy in frontline myeloma
XIIth International Myeloma Workshop in Washington, DC
Shaji Kumar, M.D.
Mayo Clinic
Rochester, Minnesota

Prolonged therapy improves quality of response, and CR associated with superior outcomes, with VMP
XIIth International Myeloma Workshop in Washington, DC
Jean Luc Harousseau, M.D.
Hôpital Hotel Dieu
Nantes, France

A Phase III Study of VMPT versus VMP in newly diagnosed elderly myeloma patients
XIIth International Myeloma Workshop in Washington, DC
Antonio Palumbo, M.D.
Ospedale Molinette
Torino, Italy

MP versus MPT in elderly myeloma patients: the final outcome of the HOVON 49 study
XIIth International Myeloma Workshop in Washington, DC
Pierre Wijermans, M.D.
University Hospital
Rotterdam, Netherlands

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycin, Dexamethasone (PAD) vs VAD as induction treatment prior to High Dose Melphalan (HDM) in patients with multiple myeloma (MM)
XIIth International Myeloma Workshop in Washington, DC
Pieter Sonneveld, M.D.
University Hospital
Rotterdam, Netherlands